On the Oppenheimer conference: 1. The presentation was clear, concise and understandable. I think Peter has improved his delivery. I cannot see how an investor could not have high degree of confidence in this technology.
2. He stated that BioPath has a 20 year patent protection (if I understood correctly).
3. I learned how to pronounce prexigeberson (emphasis on ber).
4. His slide stated there were 4 sites recruiting patients for the AML study. SJ, you heard him say six so I will check again. The slide did say that 10 sites would be involved.
5. A slide listed market cap at 90-100 Million (I think) and he stated that now it was 80-90 or 70-80 but would be improving soon.
6. I should not make a clinical statement about our CEO based on listening to him speak but he sounded short of breath and I have some concern about his health. I hope he has been evaluated and is getting good care. MD Anderson has some pretty good docs in the cardiology and pulmonary departments.
News 
Market Data 
Discover 
